There are 2934 resources available
4751 - Immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC) – a multicenter analysis
Presenter: Valerie Heong
Session: Poster Discussion – Gynaecological cancers
Resources:
Abstract
4350 - Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola) – Phase III SOLO1 trial
Presenter: Ana Oaknin
Session: Poster Discussion – Gynaecological cancers
Resources:
Abstract
2325 - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the Phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Presenter: Michael Friedlander
Session: Poster Discussion – Gynaecological cancers
Resources:
Abstract
Presentation of case/condition
Presenter: Jesus San-Miguel
Session: Defining optimal response in myeloma
Resources:
Slides
Webcast
Haematology and immunophenotyping
Presenter: Jesus San-Miguel
Session: Defining optimal response in myeloma
Resources:
Slides
Webcast
Imaging
Presenter: Sally Barrington
Session: Defining optimal response in myeloma
Resources:
Slides
Webcast
Presentation of case/condition
Presenter: Lizza Hendriks
Session: Oligorecurrent and oligoprogressive NSCLC
Resources:
Slides
Webcast
The radiotherapist’s perspective
Presenter: Suresh Senan
Session: Oligorecurrent and oligoprogressive NSCLC
Resources:
Slides
Webcast
The medical oncologist’s perspective
Presenter: Mary O'Brien
Session: Oligorecurrent and oligoprogressive NSCLC
Resources:
Slides
Webcast
Our profession’s worst nightmare
Presenter: Rick L. Haas
Session: Radiation-associated sarcoma
Resources:
Slides
Webcast